Share on StockTwits

Shares of Masimo Corp. (NASDAQ:MASI) have earned an average recommendation of “Hold” from the seven ratings firms that are currently covering the stock, Analyst Ratings Net reports. Four investment analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $28.00.

Shares of Masimo Corp. (NASDAQ:MASI) opened at 24.49 on Tuesday. Masimo Corp. has a 52-week low of $21.45 and a 52-week high of $32.20. The stock has a 50-day moving average of $23.98 and a 200-day moving average of $26.58. The company has a market cap of $1.389 billion and a price-to-earnings ratio of 21.51.

Masimo Corp. (NASDAQ:MASI) last posted its quarterly earnings results on Wednesday, April 30th. The company reported $0.30 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.29 by $0.01. The company had revenue of $139.80 million for the quarter, compared to the consensus estimate of $144.01 million. During the same quarter last year, the company posted $0.28 earnings per share. Analysts expect that Masimo Corp. will post $1.29 EPS for the current fiscal year.

MASI has been the subject of a number of recent research reports. Analysts at BTIG Research initiated coverage on shares of Masimo Corp. in a research note on Tuesday. They set a “buy” rating and a $32.00 price target on the stock. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Masimo Corp. in a research note on Friday, June 13th. They now have a $25.00 price target on the stock. Finally, analysts at Citigroup Inc. reiterated a “hold” rating on shares of Masimo Corp. in a research note on Friday, May 2nd. They now have a $29.00 price target on the stock.

Masimo Corporation is a global medical technology company that develops, manufactures, and markets noninvasive patient monitoring products.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.